Understanding HPV16 Variants and Their Cancer Risk
Author Information
Author(s): Benjamin Smith, Zigui Chen, Laura Reimers, Koenraad van Doorslaer, Mark Schiffman, Rob DeSalle, Rolando Herrero, Kai Yu, Sholom Wacholder, Tao Wang, Robert D. Burk
Primary Institution: Albert Einstein College of Medicine
Hypothesis
What genetic variations in HPV16 contribute to its oncogenic properties?
Conclusion
The study found that specific genetic variations in HPV16 are associated with increased cancer risk, particularly in certain lineages.
Supporting Evidence
- HPV16 variants show evolutionarily stable lineages with conserved diagnostic SNPs.
- The imputation algorithm accurately predicts SNPs from partial sequence data.
- Specific HPV16 SNPs were associated with increased odds ratios for cervical cancer.
- Lineage-specific SNPs were identified that may indicate higher cancer risk.
- Imputation accuracy was estimated to be over 97% for SNPs.
- Non-European HPV16 variants were found to have a stronger association with high-grade cervical neoplasia.
Takeaway
This study looks at how different versions of the HPV16 virus can affect the risk of getting cervical cancer. It found that some versions are more dangerous than others.
Methodology
The study used a reference set of 62 complete HPV16 genome sequences to analyze genetic variations and their association with cervical cancer risk through a viral genome-wide association study.
Limitations
The study's statistical power was limited, and no individual SNPs reached statistical significance.
Participant Demographics
Participants were women from Guanacaste, Costa Rica, with 115 cases of cervical intraepithelial neoplasia 3 or cancer and 297 controls with resolved HPV16 infections.
Statistical Information
P-Value
p=0.07 for overall odds ratio calculations
Confidence Interval
95% C.I. 0.95–3.18 for overall odds ratio
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website